GlassScriptPhysician profile
Carrie A Campbell
NPI 1629741913
$1,821.57
in general payments reported to CMS, 2019-2025
20 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $154 · 2024: $474 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.39 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.53 | 2022-2025 | |
| Janssen Biotech, INC. | $177.68 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $176.65 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $149.31 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $129.75 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.19 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $75.37 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $67.40 | 2023-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $58.53 | 2025 | Voquezna |
| Celgene Corporation | $49.42 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $42.11 | 2025 | Rezdiffra |
| Pfizer INC. | $34.73 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.37 | 2023-2025 | Dupixent |
| Genzyme Corporation | $29.96 | 2025 | |
| Aimmune Therapeutics, INC. | $23.94 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $17.14 | 2023 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $16.44 | 2024 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.62 | 2024 | Cyltezo |
| Celltrion USA INC. | $15.07 | 2025 | Vegzelma |
| Stryker Corporation | $14.36 | 2025 | Neptune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.